Aspirin, ASA; Butalbital; Caffeine Indications and Dosage
- headache
- migraine †
- mild pain †
- moderate pain †
† non-FDA-approved indication
Aspirin, ASA; Butalbital; Caffeine Indications and Dosage
For the treatment of occasional tension headache, occasional migraine † or co-existing migraine † and tension-type headaches:
Oral dosage (tablets or capsules containing aspirin 325 mg, butalbital 50 mg, and caffeine 40 mg):
Adults and the elderly: 1 - 2 tablets or capsules PO every 4 hours as needed. Maximum of 6 tablets or capsules per day. NOTE: According to OBRA regulations, butalbital is not to be used in a nursing home patient unless started before admission to the nursing home or given as a single dose for a medical or dental procedure. Discontinuation of butalbital should be attempted in the nursing home patient.
Children: Safe and effective use not established.
For the treatment of mild pain † and moderate pain † not related to headaches where relaxant and sedative effects are desired:
Oral dosage (tablets or capsules containing aspirin 325 mg, butalbital 50 mg, and caffeine 40 mg):
Adults and the elderly: 1 - 2 tablets or capsules PO every 4 hours as needed. Maximum of 6 tablets or capsules per day. NOTE: According to OBRA regulations, butalbital is not to be used in a nursing home patient unless started before admission to the nursing home or given as a single dose for a medical or dental procedure. Discontinuation of butalbital should be attempted in the nursing home patient.
Children: Safe and effective use not established.
Maximum Dosage Limits:
- Adults: 6 tablets or capsules/day PO.
- Elderly: 6 tablets or capsules/day PO.
- Adolescents: Safe and effective use not established.
- Children: Safe and effective use not established.
Patients with hepatic impairment:
Patients with hepatic disease may be at increased risk of salicylate-induced adverse reactions; however, no quantitative dosage recommendations are available. This combination not recommended for patients with severe hepatic disease.
Patients with renal impairment:
Dosage should be modified depending on clinical response and degree of renal impairment; no quantitative recommendations are available.
† non-FDA approved indication
[ Last revised: 11/24/2003 2:38:00 PM ]
References
. Gurvich T, Cunningham JA. Appropriate Use of Psychotropic Drugs in Nursing Homes. Am Fam Physician 2000;61:1437 - 46.
Related entries
Syndicate
|
